The requirements of this Paragraph would assist the acquirer to obtain technical expertise to serve its customers.

Paragraph VIII of the proposed Order would require ADP to obtain prior approval from the Commission for any reacquisition of the assets required to be divested. Certain acquisitions that would not require a premerger filing under the Hart-Scott-Rodino Premerger Notification Act would be subject to a prior notice requirement.

The proposed Order also would require ADP to provide periodic reports of compliance (Paragraph IX), to notify the Commission of changes in its corporate structure or status (Paragraph X), and to permit authorized representatives of the Commission access to, among other things, documents and memoranda relating to matters contained in the Order (Paragraph XI). The proposed Order would terminate twenty years from the date the Order is final.

The purpose of this analysis is to facilitate public comment on the proposed Order, and it is not intended to constitute an official interpretation of the agreement and proposed Order or to modify in any way their terms.

Donald S. Clark,

Secretary.

[FR Doc. 97–16608 Filed 6–24–97; 8:45 am]

BILLING CODE 6750–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Agency Information Collection Activities: Proposed Collections; Comment Request

The Department of Health and Human Services, Office of the Secretary will periodically publish summaries of proposed information collections projects and solicit public comments in compliance with the requirements of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995. To request more information on the project or to obtain a copy of the information collection plans and instruments, call the OS Reports Clearance Officer on (202) 690–6207.

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology.

Proposed Projects 1. Study of the Implementation of the Office of Minority Health's Bilingual/Bicultural Service Demonstration Program

New—The Office of Minority Health proposes to survey sites participating in its Bilingual/Bicultural demonstration grant program to obtain general information on how the program is being implemented.

Type of Respondents: demonstration sites; *Number of Respondents:* 47; *Burden Estimate per Response to Verification Survey:* 4 hours; *Total Burden for Verification Survey:* 188 hours; *Burden Estimate per Response to Telephone Interview:* 1 hour; *Total Burden for Telephone Interview:* 47 hours. *Total Study Burden:* 235 hours.

Send comments to Cynthia Agens Bauer, OS Reports Clearance Officer, Room 503H, Humphrey Building, 200 Independence Avenue S.W., Washington, DC, 20201. Written comments should be received within 60 days of this notice.

Dated: June 18, 1997.

Dennis P. Williams,

Deputy Assistant Secretary, Budget.

[FR Doc. 97–16643 Filed 6–24–97; 8:45 am]

BILLING CODE 4150–04–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Program Support Center; Agency Information Collection, Activities: Submission for OMB Review; Comment Request

The Department of Health and Human Services, Program Support Center, publishes a list of information collections it has submitted to the Office of Management and Budget (OMB) for clearance in compliance with the paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35) and 5 CFR 1320.5. The following are those information collections recently submitted to OMB:

1. Public Health Service (PHS) Commissioned Corps Application Forms (PHS–50 and PHS–1813)—Revision. The forms have been revised to reflect a reduction in the number and type of questions, as well as a reorganization of the questions to permit a more logical entry of data by both the applicant and the processing personnel office.

The PHS–50, Application for Appointment as a Commissioned Officer in the United States Public Health Service, is used to determine if an applicant is qualified for appointment in the Commissioned Corps of the Public Health Service. In addition, the information contained in PHS–50 establishes the basis for future assignments and benefits as a commissioned officer. *Respondents:* individual applicants seeking appointment as an officer in the Commissioned Corps of the PHS; *Total Number of Respondents:* 1,750 in calendar year 1996; *Frequency of Response:* once per applicant; *Average Burden per Response:* 1.0 hours; Estimated *Annual Burden:* 1,750 hours.

The PHS 1813, Reference Request for Applicants to the U.S. Public Health Service Commissioned Corps, is used to obtain reference information concerning applicants for appointment in the Commissioned Corps of the PHS. Each applicant is required to provide four references. *Respondents:* persons designated by applicant; *Total Number of Respondents:* 7,000; *Frequency of Response:* once per reference source; *Average Burden per Response:* .25 hour; *Estimated Annual Burden:* 1,750 hours. *Total Burden:* 3,500 hours to respondents *OMB Desk Officer:* Allison Eydt.

Copies of the information collection packages listed above can be obtained by calling the PSC Reports Clearance Officer on (301) 443–2045. Written comments and recommendations for the proposed information collection should be sent directly to the OMB desk officer designated above at the following address: Human Resources and Housing Branch, Office of Management and Budget, New Executive Office Building, Room 10235, 725 17th Street N.W., Washington, D.C. 20503.

Comments may also be sent to Douglas F. Mortl, PSC Reports Clearance Officer, Room 17A08, Parklawn Building, 5600 Fishers Lane, Rockville, MD 20857. Written comments should be received within 30 days of this notice.

Dated: June 18, 1997.

Lynnda M. Regan,

Director, Program Support Center.

[FR Doc. 97–16560 Filed 6–24–97; 8:45 am]

BILLING CODE 4160–17–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

HHS Committee on Health Data Standards: Meeting

Notice is hereby given that the U.S. Department of Health and Human

Services will hold a public meeting of its Committee on Health Data Standards and HHS Health Data Standards Implementation Teams.

Time and Date: 9:00 a.m.–5:00 p.m., July 9, 1997.

Place: Natcher Center Auditorium, Natcher Building and Conference Center, National Institutes of Health, Bethesda, Maryland.

The Natcher Center is located on the NIH campus on Center Drive off Wisconsin Avenue. The closest Metro stop is Medical Center (on the Red Line). Attendees are urged to use Metro because visitor parking at NIH is extremely limited. A map of the NIH campus is available on the World Wide Web at: http://www.nih.gov/welcome/images/nihmap.gif

Status: Open.

Purpose: The purpose of the meeting is for representatives of the U.S. Department of Health and Human Services to meet with interested and affected parties and members of the general public to describe the current status of activities relating to the adoption of health data standards pursuant to the administrative simplication provisions of Public Law 104–191, the Health Insurance Portability and Accountability Act of 1996 (HIPAA). HHS representatives will describe the HIPAA requirements for health data standards and will provide an overview of HHS efforts in implementing the law. The role of the National Committee on Vital and Health Statistics also will be described. Representatives of each of the six HHS Implementation Teams will then offer presentations on their progress to date as well as their preliminary findings relating to standards, and will respond to questions from the public.

Tentative Agenda

I. Welcome and Introductions
II. HIPAA Administrative Simplification Provisions: Background and Requirements
III. Role of the NCVHS
IV. Reports from the HHS Implementation Teams (Each report will be followed by questions from attendees.)
- Infrastructure and Crosscutting Issues
- Claims and Encounter Standards
- Unique Health Identifiers
- Enrollment and Eligibility Standards
- Coding and Classification Standards
- Security Standards

V. Conclusions

The order of agenda items is subject to change. For the final agenda, please visit the HHS Data Council's Home Page at: http://aspe.os.dhhs.gov/datacncl/

Contact Person for More Information: Additional information may be obtained from Bill Braithwaite, Office of the Assistant Secretary for Planning and Evaluation, DHHS, Room 440–D, Humphrey Building, 200 Independence Avenue S.W., Washington, D.C. 20201, telephone (202) 260–0546, or Robert Moore, Health Care Financing Administration, DHHS, 7500 Security Blvd., Baltimore, Maryland 21244, telephone (410) 786–0948.

Dated: June 19, 1997.

James Scanlon,

Director, Division of Data Policy, OPS, Office of the Assistant Secretary for Planning and Evaluation.

[FR Doc. 97–16678 Filed 6–24–97; 8:45 am]

BILLING CODE 4151–04–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 93G–0359]

Stork CFT B.V.; Withdrawal of GRAS Affirmation Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the withdrawal, without prejudice to a future filing, of a petition (GRASP 3G0397) proposing that the use of collagen fiber for use as an ingredient in human food be affirmed as generally recognized as safe (GRAS).

FOR FURTHER INFORMATION CONTACT: Mary E. LaVecchia, Center for Food Safety and Applied Nutrition (HFS–215), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–418–3072.

SUPPLEMENTARY INFORMATION: In a notice published in the **Federal Register** of December 3, 1993 (58 FR 63996), FDA announced that a petition (GRASP 3G0397) had been filed by Teepak, Inc. (now Stork CFT B.V.), c/o 1001 G St. NW., suite 500 West, Washington, DC 20001. The petition proposed that collagen fiber be affirmed as GRAS for use as an ingredient in human food. Stork CFT B.V., (formerly Teepak, Inc.) has now withdrawn the petition without prejudice to a future filing (21 CFR 171.7).

Dated: June 13, 1997.

Alan M. Rulis,

Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 97–16685 Filed 6–24–97; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 87N–0262]

Merck & Co., Inc., et al.; Withdrawal of Approval of 39 New Drug Applications, 13 Abbreviated Antibiotic Applications, and 46 Abbreviated New Drug Applications

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of 39 new drug applications (NDA's), 13 abbreviated antibiotic applications (AADA's), and 46 abbreviated new drug applications (ANDA's). The holders of the applications notified the agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.

EFFECTIVE DATE: July 25, 1997.

FOR FURTHER INFORMATION CONTACT: Olivia A. Vieira, Center for Drug Evaluation and Research (HFD–7), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–594–2041.

SUPPLEMENTARY INFORMATION: The holders of the applications listed in the table in this document have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications. The applicants have had a hearing or have, by their request, waived their opportunity for a hearing.

Application No.	Drug	Applicant
NDA 1–205	Propadrine (Phenylephrine hydrochloride) Elixir	Merck & Co., Inc., P.O. Box 4, BLA–20, West Point, PA 19486.
NDA 5–151	Percorten Acetate (desoxy-corticosterone acetate, USP Pellets.	Novartis, 556 Morris Ave., Summit, NJ 07901–1395.
NDA 5–587	Phisoderm Cream	Sterling Drug, Inc., 90 Park Ave., New York, NY 10016.
NDA 5–786	Ceepryn Concentrate Solution	Merrell Dow Research Institute, 2110 E. Galbraith Rd., Cincinnati, OH 45215–6300.